The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
Inclusion Criteria: 1. Male or female subjects aged 18 to 75 2. diagnosis of with SLE at least 6 months at screening visit 3. SLEDAE-2K≥5 4. Is receiving standard treatment for SLE and has been receiving treatment for at least 3 months. 5. At least one SLE activity manifestation (as assessed by SLEDAE-2K) Exclusion Criteria: 1. Failure to comply with the requirements of the programme 2. A female or male partner who is pregnant or breastfeeding or who plans to become pregnant during the study period 3. Previously treated with a BTK inhibitor 4. Neuropsychiatric lupus (NPSLE) 5. Has other autoimmune diseases other than SLE Note: Other protocol defined Inclusion/Exclusion criteria may apply.